Larotrectinib in patients with TRK fusion-positive solid tumours

from Listen to The Lancet Oncology · host The Lancet

Alexander Drilon (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a pooled analysis in The Lancet Oncology on the role of larotrectinib in patients with TRK fusion-positive solid tumours.

Episode metadata supplied by the publisher feed · Published Apr 7, 2020

Embed this episode

Attribution link and audio player

NOW PLAYING

Larotrectinib in patients with TRK fusion-positive solid tumours

0:00 13:25

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 13 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on April 7, 2020.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!